Daily optical coherence tomography examinations after first antivascular endothelial growth factor injections: an interventional case series

Daily optical coherence tomography examinations after first antivascular endothelial growth factor injections: an interventional case series

Author Novais, Eduardo A. Autor UNIFESP Google Scholar
Badaro, Emmerson Autor UNIFESP Google Scholar
Hirai, Flavio E. Autor UNIFESP Google Scholar
Jorge, Felipe Abdo Autor UNIFESP Google Scholar
Leal, Paula Autor UNIFESP Google Scholar
Farah, Michel Eid Autor UNIFESP Google Scholar
Rodrigues, Eduardo B. Autor UNIFESP Google Scholar
Abstract Purpose. To evaluate daily spectral-domain optical coherence tomography (SD-OCT) changes in naive-treatment patients with diagnosis of exudative age-relatedmacular degeneration (AMD) treated with intravitreous bevacizumab (1.25mg), during a 30-day follow-up period. Methods. In prospective, interventional study, SD-OCT was performed daily for 30 days after the first intravitreal injection. The baseline, initial-decrease, minimal, and final central retinal thicknesses (CRTs) were assessed. Results. Nine eyes of nine patients with neovascular AMD were enrolled. The mean baseline CRT was 625.3 +/- 182.5 mu m, and the mean final CRT was 383.4 +/- 163.0 mu m (mean difference, 206.1 +/- 167.6 mu m), a difference that reached significance (P= 0.006). After the first injection, the initial decrease in the CRT was seen as an average of one day after injection (mean CRT, 503.6 +/- 189.10 mu m

P = 0.0431). The speed of the reduction in the CRT tended to decrease by day 17. The mean CRT was 336.5 +/- 105.44 mu m and the mean minimal CRT on day 30 was 320.75 +/- 96.38 mu m. Conclusion. The CRT decreased early after the first injection. We observed a tendency for reductions in the speed with which the CRT decreased by day 17 after the first injection, which may affect retreatment regime.
Keywords Degeneration Treatments Trials
Single Intravitreal Injection
Macular Degeneration
Choroidal Neovascularization
Intraocular Pharmacokinetics
Photodynamic Therapy
Visual-Acuity
Ranibizumab
Bevacizumab
Vegf
Language English
Date 2016
Published in Journal Of Ophthalmology. New york, 2016.
ISSN 2090-004X (Sherpa/Romeo, impact factor)
Publisher Hindawi publishing corp
Origin http://dx.doi.org/10.1155/2016/6971831
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000376043400001
URI http://repositorio.unifesp.br/handle/11600/49508

Show full item record




File

Name: WOS000376043400001.pdf
Size: 3.324Mb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account